TrialESMO open2021

A randomized phase II study comparing the efficacy and safety of the glyco-optimized anti-EGFR antibody tomuzotuximab against cetuximab in patients with recurrent and/or metastatic squamous cell cancer of the head and neck - the RESGEX study.

K Klinghammer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.